Five Prints in Six Days: How to Trade the Data Gauntlet Into the September FOMC
The benchmark revision resets every assumption entering the most consequential data week of the year.
A Rising Star in Rare Disease: Roivant’s Lisraya
August 29, 2026 The first oral therapy approved for dermatomyositis is on the market, and...
Southern Company’s 3.2 GW Bet Is Now Contracted
Georgia Power’s OpenAI deal changes load outlook, and the fine print matters as much as the gigawatts.
Nvidia Is Buying the Front Door to Open-Source AI
At 86 times revenue, the Hugging Face deal is not a financial transaction. It is a competitive advantage purchase dressed…
The Orbital AI Supply Chain Nobody Is Pricing
August 28, 2026 SpaceX pulled its Starmind timeline forward. The suppliers that get paid first...
What Long-Term Apple Holders Should Do Now
A $2,000 foldable iPhone, a split cycle, and memory costs change the math for AAPL investors heading into Sept. 9.
What Warsh Says Friday Changes the Rate Picture
A divided Fed, a hawkish dissent bloc, and a chairman who refuses to telegraph moves: here is what investors should…
The Optical Complex’s Worst Day Is AAOI’s Best Argument
August 27, 2026 A $600 million equity raise torched the sector Monday. The underlying business...
Crypto Has a Date: Sept. 15. Here Is How to Trade It.
Bitcoin is up about 22% in a month on Clarity Act momentum and a short squeeze. The Senate cloture vote…
From $25B to $55B: Moderna’s Melanoma Math
The Phase 3 win validated the platform. Now the harder work begins: manufacturing every dose from scratch.